Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
The effect of a new dopaminergic agonist, piribedil, was studied in 16 patients with Parkinson's disease and compared with placebo and L-DOPA. Piribedil appeared to have a moderate therapeutic effect that was significantly less than that of L-DOPA. Tremor appeared to be the main clinical feature to benefit. Nausea, vomiting, and somnolence were most frequent during the buildup of treatment and confusion and hallucinations during long-term treatment. Piribedil caused a significant decrease in probenecid-induced accumulation of HVA in the CSF, suggesting reduced turnover of endogenous dopamine in the brain. There was a significant relationship between dopamine receptor activation by piribedil and improvement of parkinsonian disability.
D000368:Aged; D001921:Brain / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D010891:Piribedil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D012701:Serotonin / Q000378:metabolism*
D010879:Piperazines; D010919:Placebos; D012701:Serotonin; D007980:Levodopa; D006897:Hydroxyindoleacetic Acid; D010891:Piribedil; D004298:Dopamine; D006719:Homovanillic Acid